FagronARSUF -1.74%92 EV-to-FCF is 15.91 as of Jul. 12, 2026, which is 24% below its 10-year median of 21.05. GuruFocus rates ARSUF with a GF Score™ of 92/100 and a GF Value™ of $26.73. The stock has 6 warning signs investors should review. Among 562 Drug Manufacturers companies, Fagron ranks better than 60.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fagron's Enterprise Value is $2,312 Mil.
Fagron's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $145 Mil. Therefore, Fagron's EV-to-FCF for today is 15.91.
The historical rank and industry rank for Fagron's EV-to-FCF or its related term are showing as below:
ARSUF'
s EV-to-FCF Range Over the Past 10 Years
Min: 13.63 Med: 21.05 Max: 34.77
Current: 16.29
During the past 13 years, the highest EV-to-FCF of Fagron was 34.77. The lowest was 13.63. And the median was 21.05.
ARSUF's EV-to-FCF is ranked better than 60.5% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs ARSUF: 16.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-12), Fagron's stock price is $26.5296.
Fagron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $1.441. Therefore, Fagron's PE Ratio (TTM) for today is 18.41.
Fagron (OTCPK:ARSUF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fagron's share price for today is $26.5296.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fagron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $1.441.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fagron EV-to-FCF Related Terms
Fagron EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Fagron's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fagron's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fagron EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fagron's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fagron's EV-to-FCF falls into.
Fagron's current Enterprise Value is $2,312 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fagron's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fagron (ARSUF) has a EV-to-FCF of 15.91 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fagron and its competitors. This is 24% below median its historical median of 21.05. Over the past decade, Fagron's EV-to-FCF has ranged from 13.63 to 34.77. According to the industry distribution chart, Fagron ranks #222 out of 562 companies in the Drug Manufacturers industry, placing it in the top 39.5%.
Is Fagron's EV-to-FCF too high?
Fagron's current EV-to-FCF of 15.91 is 24% below median its 10-year median of 21.05. Over the past 10 years, this metric has ranged from a low of 13.63 to a high of 34.77. The Drug Manufacturers industry median EV-to-FCF is 20.96. Fagron's value of 15.91 is 24.1% below this industry median. Based on the distribution chart, Fagron ranks #222 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Fagron has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Fagron's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fagron ranks #222 out of 562 companies for EV-to-FCF. This puts Fagron in the upper half of its industry. The industry median EV-to-FCF is 20.96. Fagron's value of 15.91 is 24.1% below this benchmark. Historically, Fagron's own EV-to-FCF has ranged from 13.63 to 34.77 over the past decade. While the company's 10-year median is 21.05 vs. the industry median of 20.96, Fagron has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fagron's current EV-to-FCF of 15.91 is 24.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fagron and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fagron's current EV-to-FCF is 15.91, which is 24% below median its own 10-year median of 21.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fagron stock overvalued right now?
Fagron (ARSUF) has a current EV-to-FCF of 15.91. The stock's GF Value™ is $26.73, compared to a current price of $26.53 — trading 0.7% below its estimated fair value. The current EV-to-FCF is 15.91, which is 24% below median its 10-year median of 21.05 and 24.1% below the Drug Manufacturers industry median of 20.96. Fagron's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fagron (ARSUF), the current EV-to-FCF is 15.91 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fagron (ARSUF) Overvalued in 2026?
Based on GuruFocus' analysis, Fagron stock appears to be undervalued.
The current stock price of $26.53 is trading 0.7% below its estimated GF Value™ of $26.73.
Key valuation signals for ARSUF:
EV-to-FCF: 15.91 (24% below median its 10-year median of 21.05)
GF Value™: $26.73 vs. price of $26.53 (0.7% below fair value)
Industry Position: 24.1% below the Drug Manufacturers median (#222 of 562)
No single metric tells the full story. See the ARSUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fagron SA is a Belgium-based multinational pharmaceutical compounding company specializing in pharmaceutical compounding. It operates across the pharmaceutical compounding value chain, developing and manufacturing personalized medicines in collaboration with pharmacists, prescribers, hospitals, and other healthcare providers. The company has three segments: Essentials, Brands, and Compounding Services. The majority of the revenue is derived from the Essentials segment, which provides raw materials, equipment, packaging, and supplies for compounding to pharmacies and healthcare industries across EMEA, Latin America, and North America - Pacific. Geographically, it generates the maximum revenue from Fagron North America - Pacific.
92GF Score
Get the complete analysis for ARSUF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARSUF has been successfully added to your 
